文献速递眼底病与葡萄膜炎

玻璃体内与脉络膜上腔注射的三维转运模型

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

该研究基于兔眼玻璃体内和脉络膜上腔注射荧光素钠、贝伐珠单抗和雷珠单抗的已发表数据,构建了三维转运模型,并用于评估人眼中小分子和抗血管生成蛋白的分布。模型预测玻璃体内注射药物在玻璃体中充分混合,长期行为不依赖初始混合;视网膜药物递送受RPE通透性影响;脉络膜上腔注射对小分子更高效但短暂。

要点

  • 玻璃体内注射药物在玻璃体中充分混合,长期行为不依赖初始混合。
  • 不同药物的眼内药代动力学对清除机制敏感,视网膜递送受RPE通透性影响。
  • 脉络膜上腔注射对小分子更高效但短暂,长期抑制需频繁注射或缓释递送。

核心结论

  • 建立了玻璃体内与脉络膜上腔注射的综合三维转运模型,为测试给药途径和缓释装置提供框架。

研究设计与样本

  • 基于兔眼玻璃体内和脉络膜上腔注射荧光素钠、贝伐珠单抗和雷珠单抗的已发表数据构建三维转运模型,并应用于人眼评估小分子和抗血管生成蛋白的分布。

主要发现

  • 模型预测玻璃体内注射的药物在玻璃体中充分混合,且长期行为不依赖初始混合。
  • 不同药物的眼内药代动力学对清除机制敏感,有效视网膜药物递送受RPE通透性影响。
  • 对VEGF抗体,玻璃体内注射提供持续视网膜递送;脉络膜上腔注射对小分子更高效但短暂。
  • 通过脉络膜上腔给予抗血管生成药物长期抑制新生血管需频繁注射或缓释递送,如微粒递送抗血管生成肽。

临床怎么用

  • 模型可作为平台测试新药和现有药物的给药途径及缓释装置。
  • 选择玻璃体内或脉络膜上腔注射时需考虑药物分子大小和清除机制。
  • 若采用脉络膜上腔注射抗血管生成药物实现长期抑制,需设计频繁注射或缓释递送方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Quantitative understanding of the transport of therapeutic macromolecules following intraocular injections is critical for the design of efficient strategies in treating eye diseases, such as neovascular (wet) age-related macular degeneration (AMD) and macular edema (ME). Antiangiogenic treatments, such as neutralizing antibodies against VEGF or recently characterized antiangiogenic peptides, have shown promise in slowing disease progression. METHODS: We developed a comprehensive three-dimensional (3D) transport model for intraocular injections using published data on drug distribution in rabbit eyes following intravitreal and suprachoroidal (SC) injection of sodium fluorescein (SF), bevacizumab, and ranibizumab. The model then was applied to evaluate the distribution of small molecules and antiangiogenic proteins following intravitreal and SC injections in human eyes. RESULTS: The model predicts that intravitreally administered molecules are substantially mixed within the vitreous following injection, and that the long-term behavior of the injected drug does not depend on the initial mixing. Ocular pharmacokinetics of different drugs is sensitive to different clearance mechanisms. Effective retinal drug delivery is impacted by RPE permeability. For VEGF antibody, intravitreal injection provides sustained delivery to the retina, whereas SC injection provides more efficient, but short-lived, retinal delivery for smaller-sized molecules. Long-term suppression of neovascularization through SC administration of antiangiogenic drugs necessitates frequent injection or sustained delivery, such as microparticle-based delivery of antiangiogenic peptides. CONCLUSIONS: A comprehensive 3D model for intravitreal and SC drug injection is developed to provide a framework and platform for testing drug delivery routes and sustained delivery devices for new and existing drugs.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Bazzazi H, Lima E Silva R, et al. Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. Invest Ophthalmol Vis Sci. 2018. PMID: 30383198. doi:10.1167/iovs.17-23632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。